[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-reserve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-reserve":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,77,108,137,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100631170","amh-dynamic-changes-to-predict-ovarian-reserve-in-perimenopausal-breast-cancer-100631170",false,"NCT07497191","AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients","Inclusion Criteria:\n\n1. Female, aged 45-55 years\n2. Histologically confirmed hormone receptor-positive breast cancer\n3. Perimenopausal status defined as: (a) last menstrual period within 3 months prior to enrollment; and (b) FSH 10-40 IU\u002FL and E2 \\>20 pg\u002FmL\n4. Scheduled to receive adjuvant chemotherapy and\u002For endocrine therapy\n5. Willing to undergo serial blood sampling and complete menstrual diaries\n6. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Postmenopausal status\n2. Prior bilateral oophorectomy or pelvic radiotherapy\n3. Severe hepatic or renal dysfunction\n4. Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative breast cancer\n5. Conditions affecting ovarian hormone secretion (e.g., ovarian tumors, polycystic ovary syndrome, pituitary tumors)\n6. Current pregnancy, lactation, or planned pregnancy during follow-up\n7. Use of hormonal intrauterine devices\n8. Prior use of GnRH agonists or aromatase inhibitors","FEMALE","45 Years","55 Years",{"count":20,"type":21},300,"ESTIMATED","3 Years","OBSERVATIONAL","This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone receptor-positive breast cancer.\n\nThe study will enroll approximately 300 women aged 45-55 years with perimenopausal status confirmed by menstrual history and hormone levels (FSH 10-40 IU\u002FL, E2 \\>20 pg\u002FmL). Participants will be stratified by treatment regimen: (A) chemotherapy plus endocrine therapy, (B) chemotherapy plus targeted therapy plus endocrine therapy, and (C) endocrine therapy alone.\n\nBlood samples will be collected at seven time points to measure AMH, FSH, E2, and LH. Menstrual patterns and menopausal symptoms will be recorded prospectively. The primary outcome is the association between dynamic AMH changes and the occurrence of menopause. A predictive model will be constructed using LASSO regression and Cox proportional hazards models, with internal validation by bootstrap resampling.\n\nThe goal is to develop a clinically applicable tool to guide endocrine therapy decisions-including the duration of ovarian function suppression (OFS), choice between tamoxifen and aromatase inhibitors (AIs), and selection of CDK4\u002F6 inhibitors-as well as to provide individualized fertility preservation counseling for perimenopausal breast cancer patients.",[26,27,28],"Breast Cancer","Perimenopause","Ovarian Reserve",[30,28,31,32,33,34,35],"Anti-Müllerian Hormone","Perimenopausal Breast Cancer","Dynamic Monitoring","Predictive Model","Endocrine Therapy","Chemotherapy-Induced Amenorrhea","NOT_YET_RECRUITING","2026-03-23",{"date":39,"type":40},"2026-03-27","ACTUAL",{"date":42,"type":21},"2026-03-05",{"date":44,"type":21},"2030-03-05",{"name":46,"class":47},"Shengjing Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100629004","impact-of-surgery-for-deep-posterior-endometriosis-on-ovarian-reserve-endoro-100629004","NCT07469007","Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO)","Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve","ENDORO","Inclusion Criteria:\n\n* Female, aged 18 to 39 years old;\n* Suspected severe deep posterior pelvic endometriosis on reference pelvic MRI (ovarian kissing, obliteration of the pouch of Douglas) with concordant clinical examination, or confirmed severe deep posterior pelvic endometriosis during exploratory laparoscopy;\n* Patient affiliated with or covered by a social security plan;\n* Patient having been informed and having given her free, informed, and written consent\n\nExclusion Criteria:\n\n* Presence of ovarian involvement defined by the presence of at least one endometrioma \\>5 mm;\n* History of surgery for severe deep endometriosis;\n* Severe preoperative premature ovarian insufficiency (defined by AMH \\\u003C1ng\u002FmL and antral follicle count \\\u003C8);\n* Concurrent use of GnRH agonist therapy at or within the preceding 3 months of enrollment;\n* BMI \\>35 kg\u002Fm²;\n* Menopausal status;\n* Patient participating in another trial with an exclusion period that has not yet expired at the time of screening;\n* Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision;\n* Pregnant, breastfeeding, or postpartum woman.","18 Years","39 Years",{"count":59,"type":21},100,"INTERVENTIONAL",[62],"NA","Endometriosis is a chronic condition typically affecting women of reproductive age and often responsible for chronic pelvic pain and\u002For infertility.\n\nIts prevalence is estimated at 10% of the female population. Deep endometriosis is a specific phenotype of the disease, defined histologically by infiltration of the peritoneum exceeding 5 mm or by fibromuscular plaques infiltrating the muscularis propria of the abdominopelvic organs. It affects approximately 12 to 20% of patients with endometriosis.\n\nSurgery is one of the treatment options. Its aim is anatomical restoration, notably through complete macroscopic resection of the lesions and the release of adhesions, particularly those affecting the adnexa. While the negative impact of cystectomies on ovarian reserve is well known, the impact of surgery for severe deep endometriosis without ovarian involvement has never been studied. Yet, these procedures are regularly performed, and in the vast majority of cases on women of reproductive age. Moreover, the impression gathered in routine practice suggests a decrease in reserve parameters of around 5%. Therefore, understanding the actual impact of the procedure on ovarian reserve would, if it were concrete, allow for expanding the indications for preoperative fertility preservation to this subgroup of patients.\n\nThe main objective is to evaluate the impact of complete macroscopic resection of severe deep posterior pelvic endometriosis on the change in AMH levels at 12 months compared to an unexposed group.",[65,28],"Endometriosis","RECRUITING","2026-03-09",{"date":69,"type":40},"2026-03-13",{"date":71,"type":40},"2025-02-11",{"date":73,"type":21},"2028-02-11",{"name":75,"class":47},"Ramsay Générale de Santé",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":60,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":76},"100601294","phase-3-hcg-priming-in-women-with-diminished-ovarian-reserve-100601294","NCT07108621","hCG Priming in Women With Diminished Ovarian Reserve","Eight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF\u002FICSI - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-40 (both inclusive)\n* Regular menstrual cycle (23-35 days)\n* 1.-5. IVF\u002FICSI cycle at inclusion\n* AMH \\\u003C 6.29 pmol\u002FL (Elecsys® AMH assay)\n\nExclusion Criteria:\n\n* Uterine malformations or hydrosalpinx\n* Submucosal uterine myomas\n* Uterine polyps\n* Allergy to standard IVF\u002FICSI medication\n* Endometriosis stage III-IV\n* Preimplantation genetic testing\n* Testicular sperm aspiration\u002Fextraction\n* Ovarian enlargement or cysts (other than normally occurring corpora luteae)\n* Gynaecological haemorrhages of unknown aetiology\n* Known severe comorbidity\\*\n\n  * i.e., Insulin dependent diabetes mellitus, non-insulin dependent diabetes mellitus, gastrointestinal, cardiovascular, thromboembolic (including active thromboembolic disorders), pulmonary, liver or kidney diseases, HIV or Hepatitis B\u002FC, dysregulated thyroid disease, tumors of the hypothalamus or pituitary gland or ovarian, uterine, or mammary carcinoma.","40 Years",{"count":86,"type":21},80,[88],"PHASE3","The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)\u002Fintracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. To incorporate the strengths of a randomized controlled trial design, women will be randomized after their first ICSI treatment to receive either hCG or placebo in a double-blinded design during an eight-week priming period preceding their second ICSI treatment. The primary outcome is the number of oocytes retrieved in the second ICSI treatment.",[91,28,92],"Infertility, Female","In Vitro Fertilization (IVF)",[94,95,96,97,98],"hCG priming","Androgen priming","Diminished ovarian reserve","In vitro fertilization (IVF)","Controlled ovarian stimulation","2025-09-10",{"date":101,"type":40},"2025-09-17",{"date":103,"type":21},"2025-09",{"date":105,"type":21},"2031-03-31",{"name":107,"class":47},"Kristine Loessl",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":60,"phases":120,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100584019","phase-2-extended-lh-administration-100584019","NCT06883890","Extended LH Administration","Extended LH Administration (ELHA), a Strategy to Increase the Pool of Recruitable Antral Follicles: a Multicentric Randomized Trial","ELHA","Inclusion Criteria:\n\n1. AFC of at least 5 in the 3 months prior to the study cycle\n2. Basal AMH levels of at least 1 ng\u002Fml in the 3 months prior to the study cycle\n3. Age 25-38 at the moment of the study cycle\n4. D3 Basal LH: 1-6 IU\u002FL in the 3 months prior to the study cycle\n5. D3 Basal FSH: \\\u003C 8 IU\u002FL in the 3 months prior to the study cycle 13\n6. D3 Estradiol \\\u003C 70 pg\u002Fml in the 3 months prior to the study cycle\n7. Willing to participate\n8. Capable to understand and follow the study procedure\n9. eumenorrheic women with low LH levels candidate to IVF\u002FICSI cycle for tubal factor, male factor or for idiopathic infertility\n10. Acceptance and signature of the informed consent\n\nExclusion criteria:\n\n1. PCOS patients according to Rotterdam's criteria\n2. Patients with irregular cycles (shorter than 25 days or longer than 35 days)\n3. Patients already treated with LH priming\n4. Patients planning to undergo duo\u002Fdouble stimulation\n5. Patients with ASRM Stage III or IV endometriosis\n6. Patients with prior surgery significantly affecting ovary (ie ovariectomy, cystectomy significantly reducing ovarian volume or others) as assessed by the responsible gynecologist\n7. Previous cycle with less than 4 oocytes recovered\n8. Patients treated with hormones in the 3 months before the study\n9. Patients with an already known endocrinological disease including hypothyroidism (defined by TSH \\\u003C 4 mIU\u002FL), adrenocortical deficiency (ACTH stimulation test (250 mcg) with basal cortisol \\\u003C3 mcg or, if basal cortisol is 3-18 mcg serum level, cortisol serum level 30 minutes after the stimulation test \\\u003C18 mcg) and hyperprolactinemia (PLR \\> 25mcg\u002Fl)\n10. previous episode of OHSS or exuberant ovarian response to gonadotropins\n11. hypersensitivity to the study drug\n12. contraindication for pregnancy\n13. porphyria or a family history of porphyria\n14. history of ovarian torsion\n15. BMI \\> 30 kg\u002Fm2\n16. ovarian enlargement or ovarian cyst\n17. gynecological bleeding of unknown origin\n18. history of ovarian, breast or endometrial cancer.","25 Years","38 Years",{"count":119,"type":21},84,[121],"PHASE2","Luteinizing hormone (LH) plays an important role in follicular development, especially in the later stages of folliculogenesis. Theca interstitial cells and, later, granulosa cells express high concentrations of receptors for LH (LH-R). LH modulates the progressive remodeling and growth of the follicle .\n\nNew evidence points to a role for LH in promoting ovarian follicle growth and maturation, even at very early stages of folliculogenesis. Studies analyzing LH-R expression profiles in the ovary have shown that LH-R is moderately expressed even in the smallest follicles, during what is known as the gonadotropin-independent phase . Immunohistochemical studies that examined the localization of LH-R in human follicles through different stages of follicular development reveal that LH-R is expressed by granulosa cells and some thecal cells in small pre-antral follicles LH promotes the transition of follicles to the antral stage, thus leading to an increase in functional ovarian reserve. Early follicular stages, particularly those between the primordial and pre-antral stages, are critical as they regulate the rate of follicle recruitment. The potential roles of LH in the early follicular phase were analyzed in a prospective, randomized multicenter study using a sequential approach to stimulation with recombinant human r-LH, followed by r-FSH, in women in hypogonadotropic hypogonadism because they were profoundly down-regulated by the administration of depo agonist GnRH analog. LH treatment was associated with an increase in small antral follicles before FSH stimulation and a higher number of normally fertilized embryos. In addition, AMH hormone was found to be significantly increased in both groups during the week prior to FSH stimulation These results seem to indicate that, if the reduction in the number of antral follicles is not due to a decrease in the number of primordial follicles, but to a slowing of progression, as in the case of women with long-standing hypothalamic amenorrhea, there may be room for a therapeutic approach. This is with the aim of improving the response to ovarian stimulation of the aforementioned patients who present with anovulatory cycles and in a condition of hypogonadotropic hypogonadism.\n\nA recent case series described two patients suffering from hypothalamic amenorrhea with very low levels of endogenous gonadotropins, and ovulatory factor infertility. These patients were treated with exogenous LH for one to two months (prolonged administration of LH). Increased levels of both AMH and AFC were demonstrated, and they responded adequately to ovarian stimulation.\n\nThe purpose of this multicenter prospective randomized study follows recent publications confirming the implementation of ovarian reserve by supplementation with pretreatment with r-LH, a drug already on the market and routinely used in conventional controlled ovarian stimulation protocols.\n\nThe aim is to confirm that pretreatment with rhLH at a dose of 185.5 IU\u002Fday for 60 days can improve ovarian reserve, as indicated by increased baseline AMH and AFC, compared with no pretreatment. The primary outcome is serum AMH value after treatment with r-LH and without.\n\nThe planned duration of the study is 18 months, and a total of 84 patients are to be recruited. Patients will be randomized into two groups: group A who will receive pre-treatment with r-LH 185.5IU\u002Fday for 60 days and group B who will not receive pre-treatment.\n\nPatients will have a monitoring visit every two weeks for the duration of treatment, during which an ultrasound and blood sampling will be performed to evaluate the hormonal picture. Following pretreatment, a visit of with assessment of serum AMH and AFC value will be performed and the planned IVF cycle will be started. This will be followed by an additional final follow-up visit to collect obstetric and newborn outcomes that will be conducted by telephone",[28],[125,126,127,128],"AMH","AFC","Ovarian reserve","LH","2025-03-17",{"date":131,"type":40},"2025-03-19",{"date":129,"type":21},{"date":134,"type":21},"2026-09-01",{"name":136,"class":47},"Azienda Ospedaliero-Universitaria di Modena",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":16,"minAge":56,"maxAge":146,"enrollmentInfo":147,"targetDuration":149,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls",true,"50 Years",{"count":148,"type":21},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[152,153,28,154,155,156,157,158],"Childhood Cancer Survivors","Fertility","CED","Ovarian Reserve Markers","Cryopreservation","Alkylating Agents","Female","2024-10-30",{"date":161,"type":40},"2024-11-01",{"date":163,"type":40},"2024-10-09",{"date":165,"type":21},"2028-12-31",{"name":167,"class":47},"Centre Hospitalier Universitaire de Liege",3,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":117,"enrollmentInfo":175,"targetDuration":4,"studyType":60,"phases":177,"briefSummary":178,"conditions":179,"keywords":190,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":76},"100564741","in-vitro-maturation-of-human-eggs-100564741","NCT06633120","In Vitro Maturation of Human Eggs","Inclusion Criteria:\n\n* Infertile women diagnosed with PCOS or polycystic ovaries, or infertile women with good ovarian reserve\n* Antral follicle count (AFC) greater than 24\n* AMH greater than 3.5 ng\u002Fml\n* Body Mass Index less than 35\n* Accept to have embryos biopsied for PGT\n* Intend to perform embryo transfer within 4 months after completing the IVM cycle\n* Paternal (or donor) age \\<45, ejaculated sperm collection only (partner frozen and donor sperm acceptable), sperm morphology (strict criteria) \\>1%, motility \\> 20% and sperm count \\> 10 million per ml (so samples can be prepared through standard procedure)\n\nExclusion Criteria:\n\n* More than 2 failed IVF cycles",{"count":176,"type":21},50,[62],"CCRM Fertility, a global pioneer in fertility treatment, research and science, is seeking participants for a new study on in vitro maturation (IVM). IVM requires less hormones to stimulate the ovaries than IVF, making it more affordable than IVF with fewer side effects. Participants that qualify for the study will receive a free cycle of IVM treatment at CCRM Fertility and including a new patient consultation, fertility testing, preimplantation genetic testing for aneuploidies (PGT-A), anesthesia and some medication",[180,181,182,28,183,184,185,186,125,187,188,189],"Healthy","PCOS","PCOS (Polycystic Ovary Syndrome)","Infertility","Infertility Female","Infertility of Tubal Origin","Infertility Poly Cystic Ovary","In Vitro Maturation","IVM","IVF",[188,183,181,189],"2024-10-07",{"date":163,"type":40},{"date":194,"type":40},"2023-02-03",{"date":196,"type":21},"2030-08-30",{"name":198,"class":47},"Colorado Center for Reproductive Medicine"]